Lombard Medical has announced a stand-alone symposium and programme of presentations to mark the formal US launch of Aorfix, the company’s stent graft, at the VEITHsymposium (19–23 November, New York, USA).
CEO of Lombard Medical, Simon Hubbert, said: “Published clinical data suggest that up to 30% of patients present with tortuous abdominal aortic aneurysm anatomy. US physicians now have access to Aorfix, a highly effective, FDA-approved treatment option for such cases. VEITHsymposium is one of the most important annual gatherings of vascular surgeons from around the world and the ideal venue to formally launch Aorfix in the USA.”
Aorfix was approved by the US FDA in February this year and includes a unique label indication for the treatment of patients with neck angulations up to and including 90 degrees. Lombard Medical will be hosting a launch stand-alone symposium, where leading physicians will present clinical data and provide their first-hand experience of Aorfix, on Thursday, 21 November, 12pm–1pm.
Clinical discussions at the launch stand-alone symposium will be led by key investigators from the Pythagoras US clinical trial of Aorfix, including:
- Overall one-year results of the Aorfix Pythagoras PMA Study – Mark F Fillinger, director, Vascular Surgery Training Programs, Professor of Surgery, Geisel School of Medicine, Dartmouth and Principal Investigator for Lombard’s PMA Trial
- Anatomical angles and effect on Aorfix PMA Study results – Mahmoud B Malas, chief of Endovascular Surgery and Director of Vascular and Endovascular Clinical Research, Johns Hopkins Bayview Medical Center
- Gender and its impact on Aorfix PMA Study outcomes – William D Jordan Jr, professor of Vascular Surgery, University of Alabama School of Medicine
- Access techniques for tortuous anatomy – Jeffrey P Carpenter, chairman and chief, Department of Surgery, Cooper University Health Care
- Clinical insights from the Aorfix PMA Study – Kim J Hodgson, professor and chair, Division of Vascular Surgery, SIU School of Medicine
The following presentations highlighting Aorfix will also take place at this year’s VEITH Symposium on Friday, 22 November:
- Advantages and Limitations of the Lombard Aorfix Endograft. Now FDA Approved in the US – Mark F Fillinger
- Challenging Anatomy: Can Freedom from Adjunctive Fixation mean Freedom from Migration and Endoleak? –Brian R Hopkinson, Emeritus Professor of Vascular Surgery, University of Nottingham; consultant vascular surgeon, Queen’s Medical Centre, Nottingham, UK